ロード中...
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility
Denosumab is a breakthrough biological drug approved by the Food and Drug Administration and European Medicines Agency for the treatment of osteoporosis in 2010. It is a fully human monoclonal antireceptor activator of nuclear factor kappa-B ligand antibody, which inhibits the activity of osteoclast...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3383338/ https://ncbi.nlm.nih.gov/pubmed/22745560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S7688 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|